The role of ecto-purines in inflammation leading to demyelination - new means for therapies against multiple sclerosis;Rola ektopuryn w procesie od zapalenia do demielinizacji - perspektywy powstania nowych metod leczenia stwardnienia rozsianego

Neurologia i Neurochirurgia Polska

Volumn 45, Issue 5, 2011, Pages 489-499

  Cieślak, Marek ^a   Komoszyński, Michał ^b  

^a Pabianickie Centrum Medyczne Sp Z Oo   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Demyelination; Ecto purines; Ecto pyrimidines; Immunosuppression; Inflammation

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CHEMOKINE; CYTOKINE; NUCLEOTIDE; PURINERGIC P2 RECEPTOR;

ARTICLE; ASTROCYTE; B LYMPHOCYTE; CELL DAMAGE; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; DEMYELINATION; ENDOTHELIUM CELL; HYDROLYSIS; IMMUNE RESPONSE; INFLAMMATION; INTERACTIONS WITH NUCLEIC ACID; MICROGLIA; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PROTEIN EXPRESSION; PROTEIN SECRETION; T LYMPHOCYTE;

EID: 82855165257     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.1016/s0028-3843(14)60318-2     Document Type: Article

References (72)

1. Martino G., Adorini L., Rieckmann P. i wsp. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 2002; 1: 499-509.
2. Siffrin V., Vogt J., Radbruch H. i wsp. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010; 33: 202-210.
3. Di Virgilio F. Purinergic signaling in the immune system. A brief update. Purinergic Signal 2007; 3: 1-3.
4. Di Virgilio F., Ceruti S., Bramanti P. i wsp. Purinergic signalling in inflammation of the central nervous system. Trends Neurosci 2009; 2: 79-87.
5. Sperlagh B., Illes P. Purinergic modulation of microglial cell activation. Purinergic Signal 2007; 3: 117-127.
6. Kukulski F., Komoszyński M. E-NTPDazy - enzymy uczestnicza{ogonek}ce w procesach sygnalizacji w centralnym układzie nerwowym. Postepy Biol Komorki 2002; 3: 449-463.
7. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.
8. Bours M., Swennen E., Serafini B. i wsp. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 2006; 112: 358-404.
9. Yegutkin G. Nucleotide and nucleoside converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783: 673-694.
10. Kukulski F., Ben Yebdri F., Bahrami F. i wsp. Endothelial P2Y2 receptor regulates LPS-induced neutrophil transendothelial migration in vitro. Mol Immunol 2010; 47: 991-999.
11. Gabel Ch. P2 purinergic receptor modulation of cytokine production. Purinergic Signal 2007; 3: 27-38.
12. Wang L., Jacobsen S., Bengtsson A. i wsp. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol 2004; 5: 1-7.
13. Sitkovsky M.V., Ohta A. The "danger" sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol 2005; 22: 299-304.
14. Sitkovsky M., Lukashev D., Apasov S. i wsp. Physiological control of immune response and inflammatory tissue damage by hypoxia- inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004; 22: 657-682.
15. i/o-coupled P2Y receptors. J Neurosci 2001; 21: 1975-1982.
16. Trautmann A. Extracellular ATP in immune system: more than a just a danger signal. Sci Signal 2009; 2: 1-3.
17. Chmielewski H., Maciejek Z., Lutz W. i wsp. Zmiany ste{ogonek}żenia wolnych nukleotydów adeninowych w erytrocytach i aktywno oeci ATP-azowej cieni krwinek czerwonych chorych na stwardnienie rozsiane leczonych ACTH. Biuletyn WAM 1980; 23: 71-78.
18. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007; 87: 659-797.
19. Burnstock G. Purine-mediated signaling in pain and visceral perception. Trends Pharmacol Sci 2001; 4: 182-188.
20. Burnstock G. Purinergic nerves. Pharmacol Rev 1972; 24: 509-581.
21. Perregaux D., Gabel C.A. Interleukin1B maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 1994; 269: 15195-15203.
22. Chakfe Y., Seguin R., Antel J. i wsp. ADP and AMP induce interleukin1- β release from microglial cells through activation of ATP-primed P2X7 receptor channel. J Neurosci 2002; 22: 3061-3069.
23. Langston H., Ke Y., Gewirtz A. i wsp. Secretion of IL-2 and IFNgamma but not IL-4 by antigen-specific T cells requires extracellular ATP. J Immunol 2003; 170: 2962-2970.
24. Carroll W., Donnelly-Roberts D., Jarvis M. Selective P2X7 receptor antagonists for chronic inflammation and pain. Purinergic Signal 2009; 5: 63-73.
25. Skaper S., Debetto P., Giusti P. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J 2009; 24: 337-345.
26. Yiangou Y., Facer P., Durrenberger P. i wsp. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006; 2: 6-12.
27. Duan S., Anderson C.M., Keung E.C. i wsp. P2X7 Receptor-mediated release of excitatory amino acid from astrocytes. J Neurosci 2003; 23: 1320-1328.
28. Lister M., Sharkey J., Sawatzky D. i wsp. The role of purinergic P2X7 receptor in inflammation. J Inflammation 2007; 4: 5.
29. Hughes J., Hatcher J., Chessell I. The role of P2X7 in pain and inflammation. Purinergic Signal 2007; 3: 163-169.
30. Narcisse L., Scemes E., Zhao Y. i wsp. The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes. Glia 2005; 49: 245-258.
31. Friedle S.A., Curet M.A., Watters J.J. Recent patents on P2X(7) receptor antagonist and their potential for reducing central nervous system inflammation. Recent Pat CNS Drug Discov 2010; 5: 35-45.
32. Baxter A., Bent J., Bowers K. i wsp. Hit-to-lead studies: the discovery of potent adamantine amid P2X7 receptor antagonist. Bioorg Med Chem Lett 2003; 13: 4047-4050.
33. Romagnoli R., Baraldi P.G., Di Virgillo F. Recent progress in the discovery of antagonists acting at P2X7 receptor. Expert Opin Ther Pat 2005; 15: 271-287.
34. Schnurr M., Toy T., Shin A. i wsp. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression n human dendritic cells: a novel role for the cAMP pathway. Blood 2005; 105: 1582-1589.
35. Conigrave A.D., Fernando K.C., Gu B. i wsp. P2Y(11) receptor expression by human lymphocytes: evidence for two cAMPlinked purinorceptors. Eur J Pharmacol 2001; 426: 157-163.
36. Ecke D., Fischer B., Reiser G. Diastereoselectivity of the P2Y11 nucleotide receptor: mutation analysis. Br J Pharmacol 2008; 155: 1250-1255.
37. Marteau F., Comni D., Boeynaems J.-M. i wsp. Invovement of multiple P2Y receptors and signaling pathways in the action of adenine nucleoside diphosphates on human monocyte-derived dendritic cells. J Leukoc Biol 2004; 76: 796-803.
38. Nowak J., Zawilska J. Receptory i mechanizmy przekazywania sygnału. PWN, Warszawa 2004.
39. Stone T.W., Cerutti S., Abbracchio M.P. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009; 193: 535-587.
40. Spanevello R.M., Mazzanti C.M., Bagatini M. i wsp. Activities of the enzymes that hydrolyze adenine nucleotides in platelets from multiple sclerosis patients. J Neurol 2010; 257: 24-30.
41. Abbracchio M., Ceruti S. P1 receptors and cytokine secretion. Purinergic Signal 2007; 3: 13-25.
42. Tsutsui S., Schnermann J., Noorbakhsh F. i wsp. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelinination in a model of multiple sclerosis. J Neurosci 2004; 24: 1521-1529.
43. Braun N., Lenz C., Gillardon F. i wsp. Focal cerebral ischemia enhances glial expression of ecto-5'-nucleotidase. Brain Res 1997; 766: 213-226.
44. Hasko G., Pachwer P., Vizi E.S. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 2005; 26: 511-516.
45. Ciccarelli R., Di Iorio P., Bruno F. i wsp. Activation of A1 adenosine or mGlu3 metabotropic glutamate receptors enhances he release of nerve growth factor and S-100b protein from cultured astrocytes. Glia 1999; 27: 275-281.
46. Schwaninger M., Neher M., Viegas E. i wsp. Stimulation of interleukin- 6 secretion and gene transcription in primary astrocytes by adenosine. J Neurochem 1997; 69: 1145-1150.
47. Johnston J.B., Silva C., Gonzalez G. i wsp. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 2001; 49: 650-658.
48. Wittendorp M.C., Boddeke H.W., Biber K. Adenosine A3 receptor induced CCL2 synthesis in cultured mouse astrocytes. Glia 2004; 46: 410-418.
49. Gessi S., Varani K., Merighi S. i wsp. Adenosine and lymphocyte regulation. Purinergic Signal 2007; 3: 109-116.
50. Franco R., Casado V., Ciruela F. i wsp. Cell surface adenosine deaminase: much more than an ectoenzyme. Prog Neurobiol 1997; 52: 283-292.
51. Vivekanandhan S., Soundararajan C., Tripathi M. i wsp. Adenosine deaminase and 5'-nucleotidase activities in peripheral blood T cell of multiple sclerosis patients. Neurochem Res 2005; 30: 453-456.
52. Gołab J., Jakóbisiak M., Lasek W. i wsp. Immunologia. PWN, Warszawa 2008.
53. Robson S., Sevigny J., Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2006; 2: 409-430.
54. Borsellino G., Kleinewietfeld M., Di Mitri D. i wsp. Expression of ectonucleotidase CD39 by Fox3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225-1232.
55. Pulte E., Broekman M., Olson K. i wsp. CD39/NTPDase-1 activity and expression in normal leucocytes. Thromb Res 2007; 121: 309-317.
56. Dwyer K., Deaglio S., Gao W. i wsp. CD39 and control of cellular immune responses. Purinergic Signal 2007; 3: 171-180.
57. Spanevello R., Mazzanti C., Schmatz R. i wsp. The activity expression of NTPDase is altered in lymphocytes of multiple sclerosis patients. Clin Chim Acta 2010; 411: 210-214.
58. Matute C. Glutamate and ATP signalling in white matter pathology. J Anat 2011; 219: 53-64.
59. Matute C., Torre I., Pérez-Cerdá F. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 2007; 27: 9525-9533.
60. Matute C., Cavaliere F. Neuroglial interactions mediated by purinergic signalling in the pathophysiology of CNS disorders. Semin Cell Dev Biol 2011; 22: 252-259.
61. Sharp A.J., Polak P.E., Simonini V. i wsp. P2X7 deficiency suppresses development of experimental autoimmune ence pha lo - myelitis. J Neuroinflammation 2008; 8: 33.
62. Chen L., Brosnan C.F. Exacerbation of experimental autoimmune encephalomyelitis in P2X7R-/- mice: evidence for loss of apoptotic activity in lymphocytes. J Immunol 2006; 176: 3115-3126.
63. Amadio S., Montilli C., Magliozzi R. i wsp. P2Y12 receptor protein in cortical gray matter lesions in multiple sclerosis. Cereb Cortex 2010; 20: 1263-1273.
64. Johnston J.B., Silva C., Gonzalez G. i wsp. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 2001; 49: 650-658.
65. Mayne M., Shepel P.N., Jiang Y. i wsp. Dysregulation of adenosine A1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann Neurol 1999; 45: 633-639.
66. Moreno B., Fernandez-Diez B., Di Penta A. i wsp. Preclinical studies of methylthioadenosine for the treatment of multiple sclerosis. Mult Scler 2010; 16: 1102-1108.
67. Amorini A.M., Petzold A., Tavazzi B. i wsp. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 2009; 42: 1001-1006.
68. Lazzarino G., Amorini A.M., Eikelenboom M.J. i wsp. Cerebrospinal fluid ATP metabolites in multiple sclerosis. Mult Scler 2010; 16: 549-554.
69. Airas L., Niemela J., Yegutkin G. i wsp. Mechanism of action of IFN-β in the treatment of multiple sclerosis. A special reference to CD73 and adenosine. Ann NY Acad Sci 2007; 1110: 641-648.
70. Niemala J., Ifergan I., Yegutin G. i wsp. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier. Eur J Immunol 2008; 38: 2718-2726.
71. Foote A.K., Blakemore W.F. Inflammation stimulates remyelination in areas of chronic demyelination. Brain 2005; 128: 528-539.
72. Merrman G.H., Ma I., Shum P. i wsp. Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonist. Bioorg Med Chem Lett 2005; 15: 435-438.